PLAT and plasma cell myeloma: tPA-Ald-PM-NP, designed for the treatment of multiple myeloma, are composed of bortezomib encapsulated within platelet membranes (PMs) and modified with tissue plasminogen activator (tPA) and alendronate sodium (ALD).